These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36446654)
1. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Joshi S; Anantharaman D; Muwonge R; Bhatla N; Panicker G; Butt J; Rani Reddy Poli U; Malvi SG; Esmy PO; Lucas E; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Pillai Rameshwari Ammal Kannan T; Kartha P; Shastri SS; Sauvaget C; Radhakrishna Pillai M; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P Vaccine; 2023 Jan; 41(1):236-245. PubMed ID: 36446654 [TBL] [Abstract][Full Text] [Related]
2. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR; Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226 [TBL] [Abstract][Full Text] [Related]
3. Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine. Bhatla N; Muwonge R; Malvi SG; Joshi S; Poli URR; Lucas E; Esmy PO; Verma Y; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Vashist S; Mishra G; Jadhav R; Siddiqi M; Anantharaman D; Panicker G; Butt J; Sankaran S; Kannan TPRA; Varghese R; Kartha P; Pillai MR; Waterboer T; Müller M; Sehr P; Unger ER; Sankaranarayanan R; Basu P Hum Vaccin Immunother; 2023 Dec; 19(3):2289242. PubMed ID: 38078840 [TBL] [Abstract][Full Text] [Related]
4. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR; Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797 [TBL] [Abstract][Full Text] [Related]
6. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. Sharma H; Parekh S; Pujari P; Shewale S; Desai S; Bhatla N; Joshi S; Pimple S; Kawade A; Balasubramani L; Thomas A; Suri V; Lalwani S; Uday R; Kamath V; Mandal R; Rajeswar A; Peedicayil A; Poli UR; Banerjee D; Sankaranarayanan R; Basu P; Muwonge R; Gairola S; Dogar V; Rao H; Shaligram U Lancet Oncol; 2023 Dec; 24(12):1321-1333. PubMed ID: 37949086 [TBL] [Abstract][Full Text] [Related]
8. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923 [TBL] [Abstract][Full Text] [Related]
9. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886 [TBL] [Abstract][Full Text] [Related]
10. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. Stanley M; Joura E; Yen GP; Kothari S; Luxembourg A; Saah A; Walia A; Perez G; Khoury H; Badgley D; Brown DR Vaccine; 2021 Apr; 39(16):2214-2223. PubMed ID: 33658126 [TBL] [Abstract][Full Text] [Related]
11. Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study. Basu P; Muwonge R; Bhatla N; Nene BM; Joshi S; Esmy PO; Poli URR; Joshi G; Verma Y; Zomawia E; Shastri SS; Pimple S; Anantharaman D; Prabhu PR; Hingmire S; Sauvaget C; Lucas E; Pawlita M; Gheit T; Jayant K; Malvi SG; Siddiqi M; Michel A; Butt J; Sankaran S; Rameshwari Ammal Kannan TP; Varghese R; Divate U; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Vashist S; Mishra G; Jadhav R; Thorat R; Tommasino M; Pillai MR; Sankaranarayanan R; Papillomavirus Res; 2019 Jun; 7():75-81. PubMed ID: 30711698 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Arbyn M; Xu L; Simoens C; Martin-Hirsch PP Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723 [TBL] [Abstract][Full Text] [Related]
14. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406 [TBL] [Abstract][Full Text] [Related]
15. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort. Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576 [TBL] [Abstract][Full Text] [Related]
16. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814 [TBL] [Abstract][Full Text] [Related]
17. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort. Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. Kreimer AR; Sampson JN; Porras C; Schiller JT; Kemp T; Herrero R; Wagner S; Boland J; Schussler J; Lowy DR; Chanock S; Roberson D; Sierra MS; Tsang SH; Schiffman M; Rodriguez AC; Cortes B; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; J Natl Cancer Inst; 2020 Oct; 112(10):1038-1046. PubMed ID: 32091594 [TBL] [Abstract][Full Text] [Related]
19. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials. Baisley K; Kemp TJ; Mugo NR; Whitworth H; Onono MA; Njoroge B; Indangasi J; Bukusi EA; Prabhu PR; Mutani P; Galloway DA; Mwanzalime D; Kapiga S; Lacey CJ; Hayes RJ; Changalucha J; Pinto LA; Barnabas RV; Watson-Jones D Lancet Glob Health; 2024 Mar; 12(3):e491-e499. PubMed ID: 38365419 [TBL] [Abstract][Full Text] [Related]
20. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]